Improving productivity with model-based drug development: An enterprise perspective

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 2, 2010, Pages 263-268

  Grasela, T H ^a   Slusser, R ^b  

^a Albany Medical College   (United States)

^b Rancho Palos Verdes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DECISION MAKING; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STATISTICAL PARAMETERS;

DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; HUMANS; MODELS, STATISTICAL; PHARMACOLOGY, CLINICAL; RESEARCH;

EID: 77954887669     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.117     Document Type: Review

References (33)

1. Us Food and Drug Administration. Innovation or stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (March 2004).
2. Dixon, J., Lawton, G. & Machin, P. Vertical disintegration: a strategy for pharmaceutical businesses in 2009? Nat. Rev. Drug Discov. 8, 435 (2009).
3. Kaitin, K.I. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87, 356-361 (2010).
4. Lesko, L.J. Paving the critical path: how can clinical pharmacology help achieve the vision? Clin. Pharmacol. Ther. 81, 170-177 (2007).
5. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007)
6. Gobburu, J.V. & Lesko, L.J. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol. 49, 291-301 (2009).
7. Lockwood, P., Ewy, W., Hermann, D. & Holford, N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of efect; an example in Alzheimer's disease. Pharm. Res. 23, 2050-2059 (2006).
8. Chien, J.Y., Friedrich, S., Heathman, M.A., de Alwis, D.P. & sinha, V. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J. 7, E544-E559 (2005).
9. Bhattaram, V.A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213-221 (2007).
10. Bhattaram, V.A. et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 7, E503-E512 (2005).
11. David, E., Tramontin, T. & Zemmel, R. Pharmaceutical R&D: the road to positive returns. Nat. Rev. Drug Discov. 8, 609-610 (2009).
12. Grasela, T.H. et al. Challenges in the transition to model-based development. AAPS J. 7, E488-E495 (2005).
13. Grasela, T.H., Ludwig, E. & Fiedler-Kelly, J. Kerfufe! J. Clin. Pharmacol. 49, 386-388 (2009).
14. Tobin, F. Modeling is powerful but has far to go. Predictive Biomedicine Newsletter, 22 January 2009.
15. Orlof, J. et al. the future of drug development: advancing clinical trial design. Nat. Rev. Drug Discov. 8, 949-957 (2009).
16. grasela, T.H. et al. Pharmacometrics and the transition to model-based development. Clin. Pharmacol. Ther. 82 137-142 2007).
17. Krishna, R., schaefer, H.G. & Bjerrum, O.J. Efective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development. J. Clin. Pharmacol. 47, 738-743 (2007). (Pubitemid 46800416)
18. Wehling, M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. 8, 541-546 (2009).
19. Woodcock, J. the prospects for "personalized medicine" in drug development and drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).
20. Pisano, G.P. Science Business. (Harvard Business school Press, Boston, MA, 2006).
21. Reagan, R. Remarks at the Brandenburg gate: West Berlin, 12 June 1987 Accessed 8 september 2009.
22. Zhang, L., Pfster, M. & Meibohm, B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 10, 552-559 (2008).
23. Katzenbach, J.R. & smith, D.K. the discipline of teams. Harv. Bus. Rev. 83, 162-171 (2005).
24. Russell, R.H. & Koch, J.I. Operational Excellence: The New Lever for Proftability and Competitive Advantage. (Palladium group, Lincoln, MA, 2009).
25. Viray, R.E. & Miller, S. Role of marketing in early clinical development. Pharm. News 9, 95-101 (2002).
26. Cash Jr., J.I., Earl, M.J. & Morison, R. teaming up to crack innovation and enterprise integration. Harv. Bus. Rev. 86, 90-100 (2008).
27. Us Food and Drug Administration. Center for Drug Evaluation and Research. guidance for Industry and Review staf: target Product Profle\A strategic Development Process tool: Draft guidance (March 2007).
28. Grasela, T.H. & Dement, C.W. Engineering the pharmacometrics enterprise. In The Science of Quantitative Pharmacology (eds. Ette, E.I. & Williams, P.) 903-924 (Wiley, Hoboken, NJ, 2007).
29. Grasela T.H. et al. Informatics: the fuel for pharmacometric analysis AAPS J. 9 E84-E91 2007
30. Dahl S.G. et al. Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework Basic Clin. Pharmacol. Oxicol 106 2-12 2010
31. Gryna, F.M. Product development. In Juran's Quality Control Handbook (ed. Juran, J.M.) 13.1-13.78 (Mcgraw-Hill, New York, 1988)
32. Russell, T., Riley, S.P., Cook, J.A. & Lalonde, R.L. A perspective on the use of concentration-Qt modeling in drug development. J. Clin. Pharmacol. 48, 9-12 (2008).
33. Garnett, C.E. et al. Concentration-Qt relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J. Clin. Pharmacol. 48, 13-18 (2008).